Plasma pTau181 Reveals a Pathological Signature that Predicts Cognitive Outcomes in Lewy Body Disease.
Carla AbdelnourChristina B YoungMarian Shahid-BesantiAlena SmithEdward N WilsonJavier Ramos BenitezHillary VosslerMelanie J PlastiniJoseph R WinerGeoffrey A KerchnerBrenna CholertonKatrin I AndreassonVictor W HendersonMaya YutsisThomas J MontineLu TianElizabeth C MorminoKathleen L PostonPublished in: Annals of neurology (2024)
Our findings suggest that plasma pTau181 is a promising biomarker for concurrent ADNC and amyloidosis in LBD. Furthermore, plasma pTau181 holds potential as a prognostic, monitoring, and susceptibility/risk biomarker, predicting disease progression in LBD. ANN NEUROL 2024.